Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranicabtagene autoleucel
- Development stage
- Unknown
- Lead developer
- Shanghai Hengrun Dasheng Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Ranicabtagene autoleucel (HICARA, HR-001) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Shanghai HRAIN Biotechnology. It is engineered to target the CD19 antigen, which is highly expressed on the surface of B-cell lineage cells. The therapy involves collecting a patient's T cells, genetically modifying them to express a CAR specific for CD19, and re-infusing them into the patient. Once re-infused, these cells recognize and kill CD19-positive malignant B-cells. It has received approval in China for the treatment of adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and is being developed for B-cell acute lymphoblastic leukemia (B-ALL).
- Brand names
- HICARA
- Other names
- ranicabtagene autoleucel
02
Targets
Beyond the preview
Go deeper on ranicabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranicabtagene autoleucel.